الفهرس 
HEPATOCELLULAR CARCINOMAOnly 14 pages are availabe for public view
 |  | from | 125 |  |  |
| | | from | 125 | | |
Abstract
Background: Worldwide hepatocellular carcinoma remains one of the leading causes of cancer-related death, associated with a poor prognosis due to late diagnosis in the majority of cases, where the latest global cancer statistics indicate that liver cancer (hepatocellular carcinoma) ranks second among the causes of cancer-related deaths. Hepatocellular carcinoma mostly appears in patients with chronic hepatitis or cirrhosis in which there is continuous inflammation processes and regeneration of hepatocytes, .
Aim of The Work: The aim of this study is to assess the diagnostic and prognostic role of detection of serum level of Cyclase associated Plasma protein 2 as a biomarker for diagnosis of hepatocellular carcinoma among the Egyptian patients with chronic hepatitis c virus.
Patient and Methods: This study will be conducted on 3o patients with hepatocellular carcinoma and 30 patients with liver cirrhosis and 30 patients without evidence of HCC or liver cirrhosis as controls. This study has been carried out in the department of Internal Medicine and Gastroenterology in Ain Shams University Hospitals and Manshiet El-Bakry general hospital, Department of Gastrohepatology.
Result: In the current study, the group of HCC patients reported significant increase in the serum of CAP2 than cirrhotic patients and controls with higher sensitivity and specifity than AFP in diagnosing HCC.
Conclusion: CAP2 is significantly elevated in HCC group than in cirrhotic and control groups with better sensitivity and specificity than AFP at cut off values ≥ 28.4 pg/ml and ≥ 65 ng/ml respectively. Such results support using of CAP2 as a better diagnostic marker for HCC.